Cytek Biosciences, INC 8-K filings

Cytek Biosciences announced second quarter 2026 financial results, reporting $48.1 million in total revenue, a 6% increase year-over-year, and updated its full-year revenue guidance upwards.

Cytek Biosciences announces departure of Chief Legal Officer and Corporate Secretary, Valerie Barnett, with a severance package and consulting agreement.

Cytek Biosciences, Inc. announced that Chief Legal Officer and Corporate Secretary Valerie Barnett will step down effective June 29, 2026.

Cytek Biosciences announces the resignation of its Senior Vice President, Global Sales and Services, effective June 5, 2026.

Cytek Biosciences reported an 8% increase in Q4 2025 revenue to $62.1 million, its highest quarterly revenue, but full-year revenue grew only 1% to $201.5 million, alongside significant declines in GAAP gross profit and Adjusted EBITDA.

Cytek Biosciences announced preliminary unaudited revenue of $62 million for Q4 2025, an 8% year-over-year increase, and $201 million for the full year 2025, signaling accelerated growth.

Cytek Biosciences reported a 2% increase in total revenue to $52.3 million for Q3 2025, alongside significant declines in gross profit, net income, and Adjusted EBITDA.

Cytek Biosciences reported a 2% decrease in Q2 2025 total revenue to $45.6 million, alongside a new product launch and increased recurring revenue.

Cytek Biosciences, Inc. announced the results of its 2025 annual meeting, confirming the election of Class I directors, advisory approval of executive compensation, and ratification of its independent auditor, though one director faced significant withheld votes.

Cytek Biosciences reported a 7.6% decrease in revenue for Q1 2025, alongside strategic initiatives including a new manufacturing facility in Singapore and the launch of the Cytek Muse Micro instrument.

Cytek Biosciences reports a 3.9% increase in full-year 2024 revenue and a significant improvement in adjusted EBITDA, while providing a 2025 revenue outlook of $204 million to $212 million.

Cytek Biosciences reported preliminary full-year 2024 revenue between $200 million and $201 million, a 4% increase year-over-year, despite negative impacts from foreign exchange rates and some order delays.

Cytek Biosciences announced a 7% year-over-year increase in revenue for the third quarter of 2024, reaching $51.5 million.

Cytek Biosciences' Chief Operating Officer, Paul Christopher Williams, has resigned, effective September 27, 2024, to pursue another career opportunity.

Cytek Biosciences reported a 6% year-over-year decrease in revenue for the second quarter of 2024, primarily due to weakness in the U.S. market, despite growth in other regions and its service business.

Cytek Biosciences held its 2024 annual meeting, electing Class III directors, approving executive compensation, and ratifying the selection of Deloitte & Touche LLP as its independent auditor.

Cytek Biosciences announced a 21% increase in total revenue for the first quarter of 2024, driven by both organic growth and contributions from acquired product lines, while reaffirming its full-year revenue guidance.

Cytek Biosciences has appointed William McCombe as its new Chief Financial Officer, effective March 18, 2024, while also reaffirming its full-year 2024 revenue guidance and expectation of positive net income.

Cytek Biosciences announced a 21% increase in fourth-quarter revenue and an 18% increase in full-year revenue for 2023, alongside a positive outlook for 2024.

Cytek Biosciences has updated its severance plan, increasing benefits for executives upon termination, especially during a change in control period.